FGF13 suppresses acute myeloid leukemia by regulating bone marrow niches

Abstract

Fibroblast growth factor 13 (FGF13) is aberrantly expressed in multiple cancer types, suggesting its essential role in tumorigenesis. Hence, we aimed to explore its definite role in the development of acute myeloid leukemia (AML) and emphasize its associations with bone marrow niches. Results showed that FGF13 was lowly expressed in patients with AML and that its elevated expression was related to prolonged overall survival (OS). Univariate and multivariate Cox regression analyses identified FGF13 as an independent prognostic factor. A prognostic nomogram integrating FGF13 and clinicopathologic variables was constructed to predict 1-, 3-, and 5-year OS. Gene mutation and functional analyses indicated that FGF13 was not associated with AML driver mutations but was related to bone marrow niches. As for immunity, FGF13 was remarkably associated with T cell count, immune checkpoint genes, and cytokines. In addition, FGF13 overexpression substantially inhibited the growth and significantly induced the early apoptosis of AML cells. The xenograft study indicated that FGF13 overexpression prolonged the survival of recipient mice. Overall, FGF13 could serve as an independent prognostic factor for AML, and it was closely related to the bone marrow microenvironment.

Keywords

acute myeloid leukemia / FGF13 / prognosis / immune-related genes / bone marrow niches

References

[1] DöhnerH, WeiAH, LöwenbergB. Towards precision medicine for AML. Nat Rev Clin Oncol 2021; 18( 9): 577– 590

[2] AssiSA, ImperatoMR, ColemanDJL, PickinA, PotluriS, PtasinskaA, ChinPS, BlairH, CauchyP, JamesSR, Zacarias-CabezaJ, GildingLN, BeggsA, ClokieS, LokeJC, JenkinP, UddinA, DelwelR, RichardsSJ, RaghavanM, GriffithsMJ, HeidenreichO, CockerillPN, BoniferC. Subtype-specific regulatory network rewiring in acute myeloid leukemia. Nat Genet 2019; 51( 1): 151– 162

[3] DöhnerH, EsteyE, GrimwadeD, AmadoriS, AppelbaumFR, BüchnerT, DombretH, EbertBL, FenauxP, LarsonRA, LevineRL, Lo-CocoF, NaoeT, NiederwieserD, OssenkoppeleGJ, SanzM, SierraJ, TallmanMS, TienHF, WeiAH, LöwenbergB, BloomfieldCD. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 2017; 129( 4): 424– 447

[4] Méndez-FerrerS, BonnetD, SteensmaDP, HasserjianRP, GhobrialIM, GribbenJG, AndreeffM, KrauseDS. Bone marrow niches in haematological malignancies. Nat Rev Cancer 2020; 20( 5): 285– 298

[5] ManciniSJC, BalabanianK, CorreI, GavardJ, LazennecG, LeBousse-Kerdilès MC, LouacheF, Maguer-SattaV, MazureNM, Mechta-GrigoriouF, PeyronJF, TrichetV, HeraultO. Deciphering tumor niches: lessons from solid and hematological malignancies. Front Immunol 2021; 12 : 766275

[6] DegirolamoC, SabbàC, MoschettaA. Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23. Nat Rev Drug Discov 2016; 15( 1): 51– 69

[7] OlsenSK, GarbiM, ZampieriN, EliseenkovaAV, OrnitzDM, GoldfarbM, MohammadiM. Fibroblast growth factor (FGF) homologous factors share structural but not functional homology with FGFs. J Biol Chem 2003; 278( 36): 34226– 34236

[8] WeiEQ, SindenDS, MaoL, ZhangH, WangC, PittGS. Inducible Fgf13 ablation enhances caveolae-mediated cardioprotection during cardiac pressure overload. Proc Natl Acad Sci USA 2017; 114( 20): E4010– E4019

[9] WuQF, YangL, LiS, WangQ, YuanXB, GaoX, BaoL, ZhangX. Fibroblast growth factor 13 is a microtubule-stabilizing protein regulating neuronal polarization and migration. Cell 2012; 149( 7): 1549– 1564

[10] LuH, ShiX, WuG, ZhuJ, SongC, ZhangQ, YangG. FGF13 regulates proliferation and differentiation of skeletal muscle by down-regulating Spry1. Cell Prolif 2015; 48( 5): 550– 560

[11] OkadaT, MurataK, HiroseR, MatsudaC, KomatsuT, IkekitaM, NakawatariM, NakayamaF, WakatsukiM, OhnoT, KatoS, ImaiT, ImamuraT. Upregulated expression of FGF13/FHF2 mediates resistance to platinum drugs in cervical cancer cells. Sci Rep 2013; 3( 1): 2899

[12] LuH, YinM, WangL, ChengJ, ChengW, AnH, ZhangT. FGF13 interaction with SHCBP1 activates AKT-GSK3α/β signaling and promotes the proliferation of A549 cells. Cancer Biol Ther 2020; 21( 11): 1014– 1024

[13] JohnstoneCN, PattisonAD, HarrisonPF, PowellDR, LockP, ErnstM, AndersonRL, BeilharzTH. FGF13 promotes metastasis of triple-negative breast cancer. Int J Cancer 2020; 147( 1): 230– 243

[14] BindeaG, MlecnikB, TosoliniM, KirilovskyA, WaldnerM, ObenaufAC, AngellH, FredriksenT, LafontaineL, BergerA, BrunevalP, FridmanWH, BeckerC, PagèsF, SpeicherMR, TrajanoskiZ, GalonJ. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 2013; 39( 4): 782– 795

[15] LiR, ZhangL, QinZ, WeiY, DengZ, ZhuC, TangJ, MaL. High LINC00536 expression promotes tumor progression and poor prognosis in bladder cancer. Exp Cell Res 2019; 378( 1): 32– 40

[16] CzabotarPE, LesseneG, StrasserA, AdamsJM. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol 2014; 15( 1): 49– 63

[17] KonoplevaM, LetaiA. BCL-2 inhibition in AML: an unexpected bonus?. Blood 2018; 132( 10): 1007– 1012

[18] OtaniY, IchikawaT, KurozumiK, InoueS, IshidaJ, OkaT, ShimizuT, TomitaY, HattoriY, UnedaA, MatsumotoY, MichiueH, DateI. Fibroblast growth factor 13 regulates glioma cell invasion and is important for bevacizumab-induced glioma invasion. Oncogene 2018; 37( 6): 777– 786

[19] TurkowskiK, HerzbergF, GüntherS, BrunnD, WeigertA, MeisterM, MuleyT, KriegsmannM, SchneiderMA, WinterH, ThomasM, GrimmingerF, SeegerW, SavaiPullamsetti S, SavaiR. Fibroblast growth factor-14 acts as tumor suppressor in lung adenocarcinomas. Cells 2020; 9( 8): E1755

[20] SuT, HuangL, ZhangN, PengS, LiX, WeiG, ZhaiE, ZengZ, XuL. FGF14 functions as a tumor suppressor through inhibiting PI3K/AKT/mTOR pathway in colorectal cancer. J Cancer 2020; 11( 4): 819– 825

[21] WuX, LiM, LiY, DengY, KeS, LiF, WangY, ZhouS. Fibroblast growth factor 11 (FGF11) promotes non-small cell lung cancer (NSCLC) progression by regulating hypoxia signaling pathway. J Transl Med 2021; 19( 1): 353

[22] LiJ, CaoJ, LiP, YaoZ, DengR, YingL, TianJ. Construction of a novel mRNA-signature prediction model for prognosis of bladder cancer based on a statistical analysis. BMC Cancer 2021; 21( 1): 858

[23] LiK, TayFR, YiuCKY. The past, present and future perspectives of matrix metalloproteinase inhibitors. Pharmacol Ther 2020; 207 : 107465

[24] PietrzakJ, MirowskiM, ŚwiechowskiR, WodzińskiD, WosiakA, MichalskaK, BalcerczakE. Importance of altered gene expression of metalloproteinases 2, 9, and 16 in acute myeloid leukemia: preliminary study. J Oncol 2021; 2021 : 6697975

[25] AzevedoPL, OliveiraNCA, CorrêaS, Castelo-BrancoMTL, AbdelhayE, BinatoR. Canonical WNT signaling pathway is altered in mesenchymal stromal cells from acute myeloid leukemia patients and is implicated in BMP4 down-regulation. Transl Oncol 2019; 12( 4): 614– 625

[26] MariniJC, ForlinoA, BächingerHP, BishopNJ, ByersPH, PaepeA, FassierF, Fratzl-ZelmanN, KozloffKM, KrakowD, MontpetitK, SemlerO. Osteogenesis imperfecta. Nat Rev Dis Primers 2017; 3( 1): 17052

[27] LuP, WeaverVM, WerbZ. The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol 2012; 196( 4): 395– 406

[28] ChenW, YangZ. Identification of differentially expressed genes reveals BGN predicting overall survival and tumor immune infiltration of gastric cancer. Comput Math Methods Med 2021; 2021 : 5494840

[29] JiaYY, YuY, LiHJ. POSTN promotes proliferation and epithelial-mesenchymal transition in renal cell carcinoma through ILK/AKT/mTOR pathway. J Cancer 2021; 12( 14): 4183– 4195

[30] CharoentongP, FinotelloF, AngelovaM, MayerC, EfremovaM, RiederD, HacklH, TrajanoskiZ. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep 2017; 18( 1): 248– 262

[31] SmithIA, KnezevicBR, AmmannJU, RhodesDA, AwD, PalmerDB, MatherIH, TrowsdaleJ. BTN1A1, the mammary gland butyrophilin, and BTN2A2 are both inhibitors of T cell activation. J Immunol 2010; 184( 7): 3514– 3525

[32] JiangZ, LiuF. Butyrophilin-like 9 (BTNL9) suppresses invasion and correlates with favorable prognosis of uveal melanoma. Med Sci Monit 2019; 25 : 3190– 3198

[33] MoQ, XuK, LuoC, ZhangQ, WangL, RenG. BTNL9 is frequently downregulated and inhibits proliferation and metastasis via the P53/CDC25C and P53/GADD45 pathways in breast cancer. Biochem Biophys Res Commun 2021; 553 : 17– 24

[34] AlfaroC, SanmamedMF, Rodríguez-RuizME, TeijeiraÁ, OñateC, GonzálezÁ, PonzM, SchalperKA, Pérez-GraciaJL, MeleroI. Interleukin-8 in cancer pathogenesis, treatment and follow-up. Cancer Treat Rev 2017; 60 : 24– 31

[35] AldinucciD, BorgheseC, CasagrandeN. The CCL5/CCR5 axis in cancer progression. Cancers (Basel) 2020; 12( 7): E1765

[36] GulubovaM, AleksandrovaE, VlaykovaT. Promoter polymorphisms in TGFB1 and IL10 genes influence tumor dendritic cells infiltration, development and prognosis of colorectal cancer. J Gene Med 2018; 20( 2–3): e3005

[37] PropperDJ, BalkwillFR. Harnessing cytokines and chemokines for cancer therapy. Nat Rev Clin Oncol 2022; 19( 4): 237– 253

[38] SarterK, LeimgruberE, GobetF, AgrawalV, Dunand-SauthierI, BarrasE, Mastelic-GavilletB, KamathA, FontannazP, GuéryL, DuraesFV, LippensC, RavnU, Santiago-RaberML, MagistrelliG, FischerN, SiegristCA, HuguesS, ReithW. Btn2a2, a T cell immunomodulatory molecule coregulated with MHC class II genes. J Exp Med 2016; 213( 2): 177– 187

[39] TrinchieriG. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003; 3( 2): 133– 146

[40] PropperDJ, BalkwillFR. Harnessing cytokines and chemokines for cancer therapy. Nat Rev Clin Oncol 2022; 19( 4): 237– 253

[41] CrespoJ, WuK, LiW, KryczekI, MajT, VatanL, WeiS, OpipariAW, ZouW. Human naive T cells express functional CXCL8 and promote tumorigenesis. J Immunol 2018; 201( 2): 814– 820

[42] SantosFP, KantarjianH, CortesJ, Quintas-CardamaA. Bafetinib, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor for the potential treatment of leukemia. Curr Opin Investig Drugs 2010; 11( 12): 1450– 1465

[43] LergaA, RichardC, DelgadoMD, CañellesM, FradeP, CuadradoMA, LeónJ. Apoptosis and mitotic arrest are two independent effects of the protein phosphatases inhibitor okadaic acid in K562 leukemia cells. Biochem Biophys Res Commun 1999; 260( 1): 256– 264

[44] HortonTM, BlaneySM, LangevinAM, KuhnJ, KamenB, BergSL, BernsteinM, WeitmanS. Phase I trial and pharmacokinetic study of raltitrexed in children with recurrent or refractory leukemia: a pediatric oncology group study. Clin Cancer Res 2005; 11( 5): 1884– 1889

RIGHTS & PERMISSIONS

Higher Education Press